- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Clearpoint Neuro Inc(CLPT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CLPT
11/13/2026: CLPT (1-star) is currently NOT-A-BUY. Pass it for now.
ClearPoint Neuro Inc is a medical technology company specializing in real-time MRI-guided navigation hardware, software, and disposables for neurological and spine procedures. The company's primary business strengths lie in its proprietary navigation platform and expanding partnerships with biopharmaceutical firms developing targeted cell and gene therapies. Its main growth opportunity centers on the increasing clinical adoption of minimally invasive neurosurgery and potential commercial approvals of partner drug pipelines. Key risks include persistent net losses, hospital capital spending constraints, and intense competition from larger medical device incumbents. The stock suits growth-oriented investors willing to accept volatility in exchange for exposure to advanced neuro-technology innovations, while monitoring ongoing cash burn and partner clinical trial milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | ClearPoint offers strong top-line revenue growth potential driven by expanding neurosurgery procedures and innovative gene therapy delivery partnerships. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience sharp upside movements following positive clinical trial readouts or strong quarterly earnings beats. |
| Value investor | Weak fit | The company is currently unprofitable and trades at high price-to-sales ratios without near-term earnings or book value safety margins. |
| Dividend investor | Weak fit | ClearPoint pays no dividends and retains all capital to fund ongoing growth and operational expansion. |
| Low-risk investor | Weak fit | Small-cap medical device volatility, negative earnings, and execution risks create high volatility unsuited for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences significant price swings due to its small market capitalization and reaction to clinical or financial news. |
| Valuation risk | Medium / high | Valuation relies heavily on long-term future growth expectations rather than current positive earnings. |
| Competition risk (large medtech incumbents) | High | Well-capitalized competitors like Medtronic possess vastly larger sales channels and bundled product offerings. |
| Business quality | Medium | Proprietary technology and sticky hospital relationships indicate strong product quality, offset by lack of net profitability. |
| Dividend income | Low / none | The company does not distribute income to shareholders. |
| Execution risk | High | Success depends on successfully commercializing new products and scaling biopharma partnerships on schedule. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 271.82M USD | Price to earnings Ratio - | 1Y Target Price 21.5 |
Price to earnings Ratio - | 1Y Target Price 21.5 | ||
Volume (30-day avg) 688.0K shares | Beta 1.36 | 52 Weeks Range 8.27 - 19.63 | Updated Date 11/15/2026 |
52 Weeks Range 8.27 - 19.63 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.21 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Devices
- BUY participation
- 62.5%
- Active BUY / eligible
- 5 / 8
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -4.2% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Capital Equipment | Sales and leasing of hardware navigation systems and software licenses to hospitals and medical centers. | Provides the initial footprint in surgical suites, unlocking future recurring disposable sales. |
| Disposables and Services | Single-use sterile procedural kits, head frames, cannulas, and related clinical support services. | Acts as the recurring revenue engine that scales directly with hospital procedure volumes. |
| Bipharma Partner Services | Pre-clinical development, consulting, and navigation support for pharmaceutical companies testing gene therapies. | Offers high-value upside if partner drugs gain regulatory approval and commercial traction. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 12.11 | Enterprise Value 299.34M | Price to Sales(TTM) 5.97 |
Enterprise Value 299.34M | Price to Sales(TTM) 5.97 | ||
Enterprise Value to Revenue 6.58 | Enterprise Value to EBITDA -7.07 | Shares Outstanding 32.05M | Shares Floating 26.12M |
Shares Outstanding 32.05M | Shares Floating 26.12M | ||
Percent Insiders 6.92 | Percent Institutions 51.67 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

